Latest revenue
$0
as of 2026-03-31
Latest net income
$-79.2M
as of 2026-03-31
Net margin
—
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $6.15B
- Enterprise value
- $6.15B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $40.26
- 52-wk low
- $10.95
- Beta
- —
- Shares out
- 154.7M
5-year trend
What this company does
Item 1. Business In this Annual Report on Form 10-K, unless otherwise indicated or the context otherwise requires, all references to “we,” “our,” “us,” “Centessa,” “the Company,” and “our Company” refer to Centessa Pharmaceuticals plc and its consolidated subsidiaries. Overview We are a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. We are developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. Our strategy is a…
AI summary unavailable — showing raw filing excerpt
Generated from CNTA's filing dated 2026-03-31
Key risks
Item 1A. Risk Factors Our business involves significant risks, some of which are described below. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K and in other documents we file with the SEC, including our financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” The occurrence of any of the events or developments described below could have a material adverse effect on our business, financial condition, results of operations, growth prospects and stock price. In such an event, the market price of our ADSs could decline, and you may lose…
AI summary unavailable — showing raw filing excerpt
Generated from CNTA's filing dated 2026-03-31
Profitability
Operating margin
-1384.6%
44.6%Net margin
-1316.9%
40.3%Return on equity
-37.5%
36.1%Return on assets
-28.7%
29.7%Leverage
Debt / equity
0.30×
30.1%Long-term debt / equity
0.21×
23.0%Debt / assets
23.4%
23.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $0 | -100.0% | $-79.2M | -203.2% | — |
Q4 2025 2025-12-31 | $0 | — | $-66.2M | +40.6% | — |
Q3 2025 2025-09-30 | $0 | — | $-54.9M | -29.0% | — |
Q2 2025 2025-06-30 | $0 | — | $-50.3M | -14.9% | — |
Q1 2025 2025-03-31 | $15.0M | — | $-26.1M | +31.3% | -174.2% |
Q4 2024 2024-12-31 | $0 | — | $-111.3M | — | — |
Q3 2024 2024-09-30 | $0 | — | $-42.6M | -10.1% | — |
Q2 2024 2024-06-30 | $0 | — | $-43.8M | -76.1% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on CNTA — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$22.4M
Net activity
−$22.4M
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CNTA
Institutional value
$1.25B
Total shares held
31.6M
Distinct holders
54
-92 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Medicxi Ventures Management (Jersey) Ltd | 20.0M | $792.9M | +0 (+0.0%) | No change |
| 2 | Capital World Investors | 4.8M | $191.9M | +3.7M (+317.1%) | Added |
| 3 | FEDERATED HERMES, INC. | 2.0M | $81.4M | -292.7K (-12.5%) | Trimmed |
| 4 | ALPINE ASSOCIATES MANAGEMENT INC. | 865.5K | $34.4M | — | New |
| 5 | FRANKLIN RESOURCES INC | 684.5K | $27.2M | -1.7M (-71.1%) | Trimmed |
| 6 | BlackRock, Inc. | 625.4K | $24.8M | +32.8K (+5.5%) | Added |
| 7 | UBS Group AG | 359.9K | $14.3M | -177.6K (-33.0%) | Trimmed |
| 8 | JPMORGAN CHASE & CO | 477.6K | $13.2M | +396.1K (+486.1%) | Added |
| 9 | ROYCE & ASSOCIATES LP | 278.1K | $11.0M | -84.8K (-23.4%) | Trimmed |
| 10 | TD ASSET MANAGEMENT INC | 242.0K | $9.6M | -134.3K (-35.7%) | Trimmed |
| 11 | HighMark Wealth Management LLC | 236.8K | $9.4M | +0 (+0.0%) | No change |
| 12 | DEUTSCHE BANK AG\ | 190.0K | $7.5M | +33.8K (+21.6%) | Added |
| 13 | Legal & General Group Plc | 110.2K | $4.3M | +4.8K (+4.5%) | Added |
| 14 | Y-Intercept (Hong Kong) Ltd | 96.4K | $3.8M | +84.9K (+742.3%) | Added |
| 15 | Caitong International Asset Management Co., Ltd | 93.7K | $3.7M | +85.8K (+1090.1%) | Added |
| 16 | CITIGROUP INC | 74.3K | $3.0M | +71.6K (+2660.2%) | Added |
| 17 | Pictet Asset Management Holding SA | 96.9K | $2.7M | — | New |
| 18 | JANE STREET GROUP, LLC | 41.0K | $1.6M | -439.2K (-91.5%) | Trimmed |
| 19 | Russell Investments Group, Ltd. | 38.8K | $1.5M | -36.0K (-48.1%) | Trimmed |
| 20 | Candriam S.C.A. | 36.3K | $1.4M | -755.0K (-95.4%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once CNTA's latest filing finishes processing.